FDA sends CRL to Sydnexis for SYD-101 to slow myopia in children | Optometry Times - Clinical News

Published on October 24, 2025
The FDA acknowledged the primary efficacy end point was met but determined the data did not confirm the effectiveness of low-dose atropine in children, according to the company.
Continue reading on website
Other news

Research Indicates Specific Systemic Drugs with Ocular Adverse Reactions

October 24, 2025
Long-term use of therapeutic agents has been on the rise in recent years. Consequently, the inadvertent effects of such use makes assessment of any adverse reactions important, and that’s exactly what is outlined in a new study appearing in the International Journal of Surgery as it pertains to ocular health and vision.The FDA Adverse Event Reporting System (FAERS) was used to look for ocular adve

AAOpt 2025: This year and beyond in diabetes | Optometry Times - Clinical News

October 24, 2025
Optometry Times delivers clinical news, practice insights, and research updates by optometrists for optometrists to advance care and patient outcomes.